Target ALS awards two-year research grant to AcuraStem for advancing therapeutics targeting SYF2

Ascletis reports Phase II weight‑loss results for ASC30 depot formulation

NS Pharma and NCNP report 4.5-year brogidirsen data for DMD treatment

Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment

Koselugo approved in Canada for adults with NF1 and inoperable plexiform neurofibromas

Bristol Myers Squibb reports positive Phase 3 results for oral mezigdomide in multiple myeloma

Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis

Agilent to acquire Biocare Medical for USD950m to expand pathology portfolio

AstraZeneca and Daiichi Sankyo's Enhertu receives US priority review for post-neoadjuvant HER2-positive early breast cancer

Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial

GSK licences global rights to linerixibat to Alfasigma in USD300m deal

IDEAYA Biosciences enrols first patient in Phase 1 trial of PRMT5 inhibitor IDE892

Halozyme reports US FDA approval of TECVAYLI in combination with DARZALEX FASPRO for relapsed/refractory multiple myeloma

Servier signs definitive agreement with Day One Biopharmaceuticals

PureHealth Research launches new natural GLP-1 supplements